REVIEW

Recent advances in preoperative management of esophageal adenocarcinoma [version 1; peer review: 2 approved]

Kazuto Harada^{1,2}, Dilsa Mizrak Kaya¹, Hideo Baba², Jaffer A. Ajani¹

¹Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Holcombe Boulevard, Texas, USA

²Department of Gastroenterological Surgery, Kumamoto University, Jonjo, Kumamoto, Japan

V1 First published: 18 Apr 2017, 6(F1000 Faculty Rev):501
<https://doi.org/10.12688/f1000research.10794.1>

Latest published: 18 Apr 2017, 6(F1000 Faculty Rev):501
<https://doi.org/10.12688/f1000research.10794.1>

Abstract

Esophageal cancer is an aggressive malignancy with increasing incidence, and the prognosis of patients treated by surgery alone remains dismal. Preoperative treatment can modestly prolong overall survival. Preoperative chemotherapy or chemoradiation is the standard of care for resectable esophageal cancer (greater than clinical stage I and less than clinical stage IV). One of the challenges is to predict complete response in the surgical specimen from preoperative therapy and to avoid surgery in some patients but also predict ineffectiveness of preoperative therapy if the tumor is resistant and avoid such therapies altogether. In-depth understanding of the molecular biology could lead to personalized therapy, and in the future, clinical trials designed according to molecular features are expected. Here, we summarize preoperative treatment for esophageal adenocarcinoma and their potential.

Keywords

Esophageal cancer, preoperative therapy, personalized therapy

Open Peer Review

Approval Status

	1	2
version 1
18 Apr 2017		

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Rupert Langer**, Institute of Pathology, Bern, Switzerland
2. **Efriede Bollschweiler**, University of Cologne, Köln, Germany

Any comments on the article can be found at the end of the article.

Corresponding author: Jaffer A. Ajani (jajani@mdanderson.org)

Competing interests: The authors declare that they have no competing interests.

Grant information: This work was supported by generous grants from the Caporella, Dallas, Sultan, Park, Smith, Frazier, Oaks, Vanstekelenberg, Planjery, and Cantu Families. From the Schechter Private Foundation, Rivercreek Foundation, Kevin Fund, Myer Fund, Dio Fund, Milrod Fund, and Multidisciplinary Grants from the University of Texas M. D. Anderson Cancer Center, Houston, USA. Supported in part by the National Cancer Institute and Department of Defense awards CA138671, CA172741, CA129926, CA150334 (JAA). Supported by a grant from Program for Advancing Strategic International Networks to Accelerate the Circulation of Talented Researchers from Japan Society for the Promotion of Science (KH).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2017 Harada K *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

How to cite this article: Harada K, Mizrak Kaya D, Baba H and Ajani JA. **Recent advances in preoperative management of esophageal adenocarcinoma [version 1; peer review: 2 approved]** F1000Research 2017, 6(F1000 Faculty Rev):501

<https://doi.org/10.12688/f1000research.10794.1>

First published: 18 Apr 2017, 6(F1000 Faculty Rev):501 <https://doi.org/10.12688/f1000research.10794.1>

Introduction

Esophageal cancer (EC) is estimated to be the eighth most common cause of cancer in the world (456,000 cases) and the sixth most common cause of cancer death (400,000 deaths)¹. EC has two common histologic types: adenocarcinoma (EAC) and squamous cell carcinoma (ESCC). EAC is becoming prevalent worldwide, especially in North America and Western Europe². Esophagectomy is the most effective treatment for loco-regional control, but the 5-year survival rate after esophagectomy for locally advanced EC without preoperative treatment is less than 30%³. For early-stage EC, endoscopic resection or esophagectomy without preoperative therapy is one of the available options⁴. For the metastatic EAC, two-drug cytotoxic regimens, mainly a combination of a fluoropyrimidine and a platinum compound is recommended, and if EAC overexpresses HER2, trastuzumab should be

added to chemotherapy⁴. In case of locally advanced EC, despite radical resection, local-regional and distant recurrence develop in 33% and 20% of patients after resection, respectively⁵. The pre-existing occult micrometastases or unresected occult local disease is responsible for relapses. Interestingly, in one study, at the time of operation, 88% of patients with EC were already found to have micro-metastases in rib marrow aspirated during esophagectomy⁶. To overcome relapses after surgery, preoperative or postoperative treatments have been developed⁴. Importantly, preoperative therapy can modestly prolong overall survival (OS) and increase the R0 resection rate. R0 resection is associated with a longer survival⁷. Moreover, if preoperative therapy leads to a pathological complete response (pCR), longer OS may be expected^{8,9}. **Table 1** summarizes the preoperative therapy trials for EC conducted so far.

Table 1. Key esophageal cancer trials.

Study	Enrolled number	Treatment	Overall survival	Hazard ratio (95% confidence interval)	P value	References
Preoperative chemotherapy						
MRC OEO2	802	CF → surgery (n = 400) Surgery (n = 402)	5-year rate: 23% 5-year rate: 17%	0.84 (0.72-0.98)	0.03	11
FNCLCC and FFCD	224	CF → surgery (n = 113) Surgery (n = 111)	5-year rate: 38% 5-year rate: 24%	0.69 (0.50-0.95)	0.02	13
MAGIC	503	ECX → surgery → ECX (n = 250) Surgery (n = 253)	5-year rate: 36% 5-year rate: 23%	0.75 (0.60-0.93)	0.009	12
INT 113	440	CF → surgery (n = 213) Surgery (n = 227)	Median: 14 months Median: 16 months	1.04 (0.84-1.29)	0.53	15
MRC OEO5	897	ECF → surgery (n = 446) CF → surgery (n = 451)	3-year rate: 39% 3-year rate: 42%	0.92 (0.79-1.08)	0.30	14
Preoperative chemoradiotherapy						
CROSS	368	Taxol/carbo/41.4 Gy → surgery (n = 180) Surgery (n = 188)	Median: 48 months Median: 24 months	0.68 (0.53-0.88)	0.003	18
FFCD 9901	195	CF/45 Gy → surgery (n = 98) Surgery (n = 97)	5-year rate: 41% 5-year rate: 33%	0.99 (0.69-1.30)	0.94	21
CALGB 9781	56	CF/50.4 Gy → surgery (n = 30) Surgery (n = 26)	5-year rate: 39% 5-year rate: 16%	- (0.17-0.68)	0.002	20
Preoperative chemotherapy vs. preoperative chemoradiotherapy						
POET	119	CF/30 Gy → surgery (n = 60) CF → surgery (n = 59)	3-year rate: 47% 3-year rate: 27%	0.67 (0.47-1.07)	0.07	22
Burmeister <i>et al.</i>	75	CF/35 Gy → surgery (n = 39) CF → surgery (n = 36)	Median: 32 months Median: 29 months	-	0.83	23
NeoRes	181	CF/40 Gy → surgery (n = 91) CF → surgery (n = 90)	3-year rate: 47% 3-year rate: 49%	-	0.77	24

CALGB, Cancer and Leukemia Group B; CF, cisplatin and 5 fluorouracil; CROSS, Chemoradiotherapy for esophageal Cancer Followed by Surgery Study; ECF, epirubicin, cisplatin, and fluorouracil; ECX, epirubicin, cisplatin and capecitabine; FFCD, Fédération Francophone de Cancérologie Digestive; FNCLCC, Fédération Nationales des Centres de Lutte Contre le Cancer; MAGIC, Medical Research Council Adjuvant Gastric Infusional Chemotherapy; MRC, United Kingdom Medical Research Council; POET, Preoperative Chemotherapy or Radiochemotherapy in Esophago-gastric Adenocarcinoma.

Preoperative chemotherapy

Several trials have produced mixed results. Firstly, the United Kingdom Medical Research Council (MRC) esophageal cancer trial (OEO2) recruited 802 patients (EAC: 67%) and randomly assigned them to two treatment groups: 400 to surgery plus perioperative chemotherapy—two cycles of FP (cisplatin and fluorouracil)—and 402 to surgery alone. As compared with the surgery group, the perioperative chemotherapy group had a favorable OS (5-year rate: 23% versus 17%; hazard ratio [HR] 0.84; 95% confidence interval [CI] 0.72 to 0.98; $P = 0.03$), thus showing only marginal benefit^{10,11}. The other two trials added postoperative chemotherapy to preoperative chemotherapy. The Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial evaluated the effect of perioperative chemotherapy—three preoperative and three postoperative cycles of ECF (epirubicin, cisplatin, and fluorouracil)—for resectable gastro-esophageal (GE) adenocarcinoma¹². Five hundred and three patients were randomly assigned to two treatment groups: 250 to surgery plus perioperative chemotherapy and 253 to surgery alone. As compared with the surgery-alone group, the perioperative chemotherapy group had a favorable OS (5-year rate: 36% versus 23%; HR 0.75; 95% CI 0.60 to 0.93; $P = 0.009$). However, only 25% of patients in this trial had EAC or GE junction involvement. Finally, in the Fédération Nationale des Centres de Lutte Contre le Cancer/Fédération Francophone de Cancérologie Digestive (FNCLCC/FFCD) trial, 224 patients were randomly assigned to two treatment groups: 113 to surgery plus perioperative chemotherapy (two or three preoperative and three or four postoperative cycles of CF) and 111 to surgery alone¹³. In this trial, 75% of patients had EAC. Compared with the surgery-alone group, the perioperative chemotherapy group had had a favorable OS (5-year rate: 38% versus 24%; HR 0.69; 95% CI 0.50 to 0.95; $P = 0.02$). Moreover, perioperative chemotherapy significantly increased the R0 resection rate (84% versus 73%; $P = 0.04$). These trial results were considered acceptable, and perioperative chemotherapy became standard therapy in Europe. Recently, the MRC-OEO5 trial compared two chemotherapy regimens: two cycles of FP and four cycles of ECX (epirubicin, cisplatin, and capecitabine)¹⁴. The ECX group had a higher R0 resection rate and pCR; however, there was no OS benefit for ECF compared with FP (3-year rate: 42% versus 39%; HR 0.92; 95% CI 0.79 to 1.08; $P = 0.30$). Furthermore, chemotherapy toxicity was higher in the ECX group¹⁴. This trial suggests that preoperative chemotherapy with more drugs and longer duration is not worthwhile and the addition of epirubicin does not provide any advantage.

The first and only study conducted in the US was the RTOG trial 8911 (USA Intergroup 113), which demonstrated no advantage from the addition of preoperative chemotherapy to surgery^{15,16}. Thus, enthusiasm for preoperative chemotherapy has been low in the US and preoperative chemoradiation has been favored.

Preoperative chemoradiation

A prior meta-analysis proposed that preoperative chemoradiation may be beneficial; however, meta-analyses are only hypothesis-generating¹⁷. In 2012, the Chemoradiotherapy for esophageal Cancer Followed by Surgery Study (CROSS) trial produced favorable results for patients who received preoperative chemoradiation over surgery alone¹⁸. Three hundred sixty-eight

resectable but selected patients with EC (EAC: 75%) were randomly assigned to two treatment groups: 180 to surgery plus preoperative chemoradiation and 188 to surgery alone. The long-term result of the CROSS study showed that the median OS for the preoperative chemoradiation group was significantly longer than that for the surgery-alone group (median of 48.6 versus 24.0 months; HR 0.68; 95% CI 0.53 to 0.88; $P = 0.003$)¹⁹. Importantly, the benefit for patients with ESCC was higher than for patients with EAC: Median OS rates for patients with ESCC were 81.6 months in the preoperative chemoradiation group and 21.1 months in the surgery-alone group (HR 0.48; 95% CI 0.28 to 0.83; $P = 0.008$), whereas the rates for patients with EAC were 43.2 months in the preoperative chemoradiation group and 27.1 months in the surgery-alone group (HR 0.73; 95% CI 0.55 to 0.98; $P = 0.038$)¹⁹. The rate of R0 resection increased because of preoperative chemoradiation. A previous prospective randomized CALGB 9781 trial compared surgery plus preoperative chemoradiation (cisplatin and fluorouracil with 50.4-Gy concurrent radiotherapy) and surgery alone and showed benefit for preoperative chemoradiation²⁰. However, this trial assessed only 56 patients (EAC: 75%).

The benefit from preoperative chemoradiation for patients with early-stage EC remains debatable. The result of the FFCD 9901 trial, which compared the surgery-alone group ($n = 97$, EAC: 28%) with the preoperative chemoradiation group ($n = 98$, EAC: 31%), unfortunately did not show an increase in the R0 resection rate or OS benefit but did have an increase in postoperative mortality²¹.

The type of chemotherapy agents and radiation dose differ among trials. The CROSS study used paclitaxel and carboplatin plus 41.4-Gy concurrent radiotherapy; on the other hand, the FFCD 9901 study used CF plus 45-Gy concurrent radiotherapy. Although the OS benefit from preoperative chemotherapy is modest to marginal, the types of combinations have varied (FP or ECF regimen)^{12,13}. In the current National Comprehensive Cancer Network guidelines, ECF has been downgraded on the basis of the OEO5 trial results¹⁴. Importantly, no trial has been completed that compared preoperative chemotherapy with preoperative chemoradiation. An ongoing trial might settle this issue. The PROTECT (Preoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer) study (NCT02359968) is comparing carboplatin and paclitaxel with FOLFOX during radiation. Another phase II trial (NCT01843829) is comparing carboplatin and paclitaxel with oxaliplatin and capecitabine. Additionally, the Neo-AEGIS trial (NCT01726452) is currently comparing the CROSS regimen with the MAGIC regimen. Results are expected in the near future.

Chemotherapy and chemoradiation

A recent meta-analysis compared preoperative chemoradiotherapy ($n = 1,078$) and chemotherapy ($n = 1,141$) for both EAC and ESCC, showing better OS of preoperative chemoradiation but not to a significant degree (HR 0.88; 95% CI 0.76 to 1.01; $P = 0.07$)¹⁷. To date, three randomized trials have compared preoperative chemoradiotherapy with chemotherapy, but none showed a benefit in OS of preoperative chemoradiation. The Preoperative Chemotherapy or Radiochemotherapy in Esophago-gastric Adenocarcinoma (POET) trial failed to recruit a sufficient number to

document an OS advantage for preoperative chemoradiation, and the trial had to be terminated early²². The pCR rate was higher with preoperative chemoradiation compared with preoperative chemotherapy (15.6% versus 2.0%)²². Another phase II trial also showed no benefit from preoperative chemoradiation for patients with EAC; the median OS was 32 months from preoperative chemoradiation compared with 29 months from preoperative chemotherapy ($P = 0.83$)²³. Another trial compared neoadjuvant chemotherapy with chemoradiotherapy in resectable cancer of the esophagus and gastric cardia patients ($n = 181$ with 73% EAC), and although chemoradiation resulted in a higher pCR rate (28% versus 9%), higher R0 resection rate (87% versus 74%), and a lower rate of lymph nodal metastases (35% versus 62%), there was no OS benefit (3-year OS: 49% versus 47%; $P = 0.77$)²⁴.

Our group retrospectively reviewed sequential phase II/III trials performed at the University of Texas M.D. Anderson Cancer Center, showing that compared with preoperative chemotherapy, preoperative chemoradiation exhibited a longer OS ($P = 0.046$) and disease-free survival ($P = 0.015$) and the higher pCR rate ($P < 0.001$)²⁵.

Induction chemotherapy followed by preoperative chemoradiation

Our group had proposed a strategy of induction chemotherapy before preoperative chemoradiation²⁶. To document whether there is any benefit to the addition of induction chemotherapy, we reported a randomized phase II trial that compared induction chemotherapy followed by preoperative chemoradiation with preoperative chemoradiation only. One hundred twenty-six patients with localized EAC were randomly assigned to one of two groups. The median OS rates with and without induction chemotherapy were 43.6 and 45.6 months, respectively. The pCR rates were 13% in the no induction chemotherapy group and 26% in the induction chemotherapy group ($P = 0.094$), concluding that induction chemotherapy did not appear to benefit these patients²⁷. However, subgroup analysis showed that induction chemotherapy had a considerable benefit for only those patients who had a well-moderate differentiated tumor²⁸.

Preoperative treatment with molecular targeting drug

Currently, there is no evidence that the addition of a targeted drug benefits to patients with localized EC. In patients with advanced EAC or gastric cancer, the ToGA (Trastuzumab for Gastric Cancer) trial showed that the addition of HER2 inhibitor, trastuzumab, to chemotherapy had modest benefit²⁹. However, the benefit of trastuzumab in the neoadjuvant setting is not established. In Japan, a phase II trial is evaluating S-1 plus cisplatin with or without trastuzumab in the neoadjuvant setting for HER2-positive gastric or esophagogastric junction adenocarcinoma³⁰. Epidermal growth factor receptor (EGFR) inhibitors have been evaluated in this setting^{31–34} on the basis of a tantalizing phase II study which added cetuximab to chemoradiation and produced a pCR rate of 27%³³. However, two phase III trials that added an EGFR inhibitor to dCRT (definitive chemoradiation) failed to show survival benefit^{31,35}. In addition, bevacizumab or erlotinib was evaluated with preoperative chemoradiation but did not demonstrate survival benefit or improvement in the pCR rate³⁶.

Future perspective

Approximately 25% of patients who undergo preoperative chemoradiation achieve a pCR¹⁸. If one could predict the possibility of pCR with a high level of certainty, then novel strategies to preserve the esophagus could be implemented. However, there are no useful clinical variables including positron emission tomographic (PET) changes and there are no reliable biomarkers for such a prediction at the moment. A clinical CR defined as endoscopic biopsies without cancer cells and PET scan with physiologic uptake provides an OS benefit³⁷ but does not correlate with pCR³⁸. Therefore, we recommend that all patients eligible for surgery proceed to surgery after recovering from chemoradiation.

Metabolic imaging with 18-fluorodeoxy-glucose positron emission computed tomography was assessed in various circumstances. Our group reported that PET parameters could correlate with prolonged OS but could not predict pCR³⁹. Interestingly, the Municon I and II trials evaluated treatment modifications according to PET responses for patients with EAC^{40,41}. In the Municon II trial, PET non-responders from preoperative chemotherapy had chemoradiation before surgery; however, non-responders still had an unfavorable prognosis, suggesting that primary resistance cannot be overcome by simply changing therapy. Thus, in-depth study of the tumor biology is warranted and may contribute to personalize therapy.

Recently, whole-genome analyses of EAC have been reported^{42–45}. The Cancer Genome Atlas reported an integrated genomic landscape in EC, showing that genomic characterization of EAC was different from that of ESCC but similar to that of gastric cancer subtype “CIN, chromosomal instability”^{46,47}. Mutations in *TP53*, *CDKN2A*, *ARID1A*, and *SMAD4* were common in EAC. Amplifications in *ERBB2*, *VEGFA*, *GATA4*, and *GATA6* were common in EAC. A positive result for microsatellite instability or Epstein-Barr virus was rare in EAC. However, there were some differences between EAC and gastric cancer subtyped with CIN. Compared with gastric cancer, EAC had more frequent CpG hyper-methylation phenotype, *VEGFA* and *MYC* amplifications and mutation of *SMARCA4*, deletion of tumor suppressor *RUNX1*, *FHIT*, and *WWOX*, and lower *APC* pathway activation⁴⁶. The molecular features of EAC were significantly different from that of ESCC. ESCC had significantly mutated genes, such as *TP53*, *NFE2L2*, *MLL2*, *ZNF750*, *NOTCH1*, and *TGFBR2*, and specific somatic copy number alterations, such as amplifications of *SOX2*, *TERT*, *FGFR1*, *MDM2*, and *NKX2-1* and deletion of *RB1*. Compared with EAC, inactivation of *CDKN2A*, amplification of *CCND1* and *TP63/SOX2*, and alterations of histone-modifying factors were more common in ESCC; conversely, *ERBB2* alterations were rare, suggesting that molecular targeting can differ between EAC and ESCC⁴⁶. Secrier *et al.* reported whole-genome sequencing in 129 EAC samples and classified EAC into three groups: C>A/T dominant (29%), DNA damage repair (DDR) impaired (18%), and mutagenic (53%)⁴⁵. The report recommends that, in some patients, the combination of anti-*ERBB2* and anti-MET inhibition might prove useful. In the presence of DDR impairment, inhibition by poly ADP ribose polymerase (PARP) inhibitor in combination with DNA-damaging agent might prove useful. Recently, immune-checkpoint pathways, such as T lymphocyte-associated antigen 4 (CTLA-4) and programmed

death protein 1/its ligand (PD-1/PD-L1), have received much attention⁴⁸. Therefore, tumors that have high mutation load may be amenable to immune-checkpoint inhibitors⁴⁹.

Several biomarkers that may be associated with response to preoperative therapy have been explored⁵⁰. For instance, 3'-untranslated region polymorphisms of thymidylate synthase may predict a response to 5-fluorouracil (5-FU)-based chemoradiation⁵¹. Overexpression of excision repair cross-complementation group 1 may be associated with chemoradiation response, especially with platinum agent⁵². MicroRNAs also have potential as predictive markers⁵³. Hale *et al.* reported that the proportion of tumor in biopsy tissue can predict preoperative chemotherapy response⁵⁴; however, these data need to be validated and combined with biomarkers.

Recently, liquid biopsy has been actively studied and is of considerable interest⁵⁵. Tumor-derived biomarkers in the bloodstream, such as circulating tumor cells (CTCs), cell-free DNA (ctDNA), and exosomes, have the potential to predict early treatment response^{56,57}. For instance, in several cancers, changes in CTC count were associated with response to treatment^{58,59}. In colorectal cancer, during treatment, mutation or copy number status in ctDNA can be dynamically monitored^{60,61}. Further studies and clinical applications are expected.

Conclusions

This review described an understanding of preoperative therapy for EC. The benefits of preoperative treatment, and preoperative chemoradiation in particular, have been established. Currently, preoperative chemoradiation is preferred over preoperative chemotherapy in the US. Head-to-head comparison of preoperative

chemotherapy versus preoperative chemoradiation is not completed as it is a subject of ongoing trials. A further challenge is to identify patients who are destined to achieve a pCR. CTCs or ctDNA might prove useful in surveillance after therapy and occasionally for selection of therapy.

Author contributions

KH helped to conceive the study and prepared the first draft of the manuscript. DK and JA helped to conceive the study. All authors contributed to the preparation of the manuscript and were involved in the revision of the draft and have agreed to the final content.

Competing interests

The authors declare that they have no competing interests.

Grant information

This work was supported by generous grants from the Caporella, Dallas, Sultan, Park, Smith, Frazier, Oaks, Vanstekelenberg, Planjery, and Cantu Families. From the Schecter Private Foundation, Rivercreek Foundation, Kevin Fund, Myer Fund, Dio Fund, Milrod Fund, and Multidisciplinary Grants from the University of Texas M. D. Anderson Cancer Center, Houston, USA. Supported in part by the National Cancer Institute and Department of Defense awards CA138671, CA172741, CA129926, CA150334 (JAA). Supported by a grant from Program for Advancing Strategic International Networks to Accelerate the Circulation of Talented Researchers from Japan Society for the Promotion of Science (KH).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Ferlay J, Soerjomataram I, Dikshit R, *et al.*: **Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.** *Int J Cancer.* 2015; **136**(5): E359–86.
[PubMed Abstract](#) | [Publisher Full Text](#)
2. Lagergren J, Bergström R, Lindgren A, *et al.*: **Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma.** *N Engl J Med.* 1999; **340**(11): 825–31.
[PubMed Abstract](#) | [Publisher Full Text](#)
3. Hirst J, Smithers BM, Gotley DC, *et al.*: **Defining cure for esophageal cancer: analysis of actual 5-year survivors following esophagectomy.** *Ann Surg Oncol.* 2011; **18**(6): 1766–74.
[PubMed Abstract](#) | [Publisher Full Text](#)
4. Ajani JA, D'Amico TA, Almhanna K, *et al.*: **Esophageal and esophagogastric junction cancers, version 1.2015.** *J Natl Compr Canc Netw.* 2015; **13**(2): 194–227.
[PubMed Abstract](#)
5. Mariette C, Balon JM, Piessen G, *et al.*: **Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease.** *Cancer.* 2003; **97**(7): 1616–23.
[PubMed Abstract](#) | [Publisher Full Text](#)
6. O'Sullivan GC, Sheehan D, Clarke A, *et al.*: **Micrometastases in esophagogastric cancer: high detection rate in resected rib segments.** *Gastroenterology.* 1999; **116**(3): 543–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
7. Rice TW, Rusch VW, Apperson-Hansen C, *et al.*: **Worldwide esophageal cancer collaboration.** *Dis Esophagus.* 2009; **22**(1): 1–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
8. Donahue JM, Nichols FC, Li Z, *et al.*: **Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival.** *Ann Thorac Surg.* 2009; **87**(2): 392–8; discussion 398–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
9. Berger AC, Farma J, Scott WJ, *et al.*: **Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival.** *J Clin Oncol.* 2005; **23**(19): 4330–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
10. Medical Research Council Oesophageal Cancer Working Group: **Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial.** *Lancet.* 2002; **359**(9319): 1727–33.
[PubMed Abstract](#) | [Publisher Full Text](#)
11. Allum WH, Stenning SP, Bancewicz J, *et al.*: **Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.** *J Clin Oncol.* 2009; **27**(30): 5062–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
12. Cunningham D, Allum WH, Stenning SP, *et al.*: **Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.** *N Engl J Med.* 2006; **355**(1): 11–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**

13. **F** Ychou M, Boige V, Pignon JP, *et al.*: Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. *J Clin Oncol.* 2011; 29(13): 1715–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
14. Alderson D, Langley RE, Nankivell MG, *et al.*: Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072). *J Clin Oncol.* 2015; 33(suppl): abstr 4002.
[Reference Source](#)
15. Kelsen DP, Ginsberg R, Pajak TF, *et al.*: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. *N Engl J Med.* 1998; 339(27): 1979–84.
[PubMed Abstract](#) | [Publisher Full Text](#)
16. Kelsen DP, Winter KA, Gunderson LL, *et al.*: Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. *J Clin Oncol.* 2007; 25(24): 3719–25.
[PubMed Abstract](#) | [Publisher Full Text](#)
17. Sjoquist KM, Burmeister BH, Smithers BM, *et al.*: Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. *Lancet Oncol.* 2011; 12(7): 681–92.
[PubMed Abstract](#) | [Publisher Full Text](#)
18. **F** van Hagen P, Hulshof MC, van Lanschot JJ, *et al.*: Preoperative chemoradiotherapy for esophageal or junctional cancer. *N Engl J Med.* 2012; 366(22): 2074–84.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
19. **F** Shapiro J, van Lanschot JJ, Hulshof MC, *et al.*: Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. *Lancet Oncol.* 2015; 16(9): 1090–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
20. Tepper J, Krasna MJ, Niedzwiecki D, *et al.*: Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. *J Clin Oncol.* 2008; 26(7): 1086–92.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. **F** Mariette C, Dahan L, Mornex F, *et al.*: Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. *J Clin Oncol.* 2014; 32(23): 2416–22.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
22. Stahl M, Walz MK, Stuschke M, *et al.*: Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. *J Clin Oncol.* 2009; 27(6): 851–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
23. Burmeister BH, Thomas JM, Burmeister EA, *et al.*: Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the esophagus? A randomised phase II trial. *Eur J Cancer.* 2011; 47(3): 354–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
24. **F** Klevebro F, Alexandersson von Döbeln G, Wang N, *et al.*: A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastro-oesophageal junction. *Ann Oncol.* 2016; 27(4): 660–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
25. Swisher SG, Hofstetter W, Komaki R, *et al.*: Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer. *Ann Thorac Surg.* 2010; 90(3): 892–8; discussion 898–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Ajani JA, Komaki R, Putnam JB, *et al.*: A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. *Cancer.* 2001; 92(2): 279–86.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. **F** Ajani JA, Xiao L, Roth JA, *et al.*: A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. *Ann Oncol.* 2013; 24(11): 2844–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
28. Shimodaira Y, Slack RS, Chen HC, *et al.*: Influence of induction chemotherapy (IC) in trimodality-eligible esophageal cancer patients: Secondary analysis of a randomized trial. *J Clin Oncol.* 2016; 34(suppl): abstr 4027.
[Reference Source](#)
29. **F** Bang YJ, van Cutsem E, Feyereislova A, *et al.*: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet.* 2010; 376(9742): 687–97.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
30. Kataoka K, Tokunaga M, Mizusawa J, *et al.*: A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger Study). *Jpn J Clin Oncol.* 2015; 45(11): 1082–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
31. **F** Crosby T, Hurt CN, Falk S, *et al.*: Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/- cetuximab in oesophageal cancer. *Br J Cancer.* 2017; 116(6): 709–716.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
32. Ruhstaller T, Pless M, Dietrich D, *et al.*: Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06). *J Clin Oncol.* 2011; 29(6): 626–31.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Safran H, Suntharalingam M, Dipetrillo T, *et al.*: Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. *Int J Radiat Oncol Biol Phys.* 2008; 70(2): 391–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
34. **F** Becerra CR, Hanna N, McCollum AD, *et al.*: A phase II study with cetuximab and radiation therapy for patients with surgically resectable esophageal and GE junction carcinomas: Hoosier Oncology Group G05-92. *J Thorac Oncol.* 2013; 8(11): 1425–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
35. Suntharalingam M, Winter K, Ilson DH, *et al.*: The initial report of RTOG 0436: A phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for patients with esophageal cancer treated without surgery. *J Clin Oncol.* 2014; 32(suppl 3): abstr LBA6.
[Publisher Full Text](#)
36. **F** Bendell JC, Meluch A, Peyton J, *et al.*: A phase II trial of preoperative concurrent chemotherapy/radiation therapy plus bevacizumab/erlotinib in the treatment of localized esophageal cancer. *Clin Adv Hematol Oncol.* 2012; 10(7): 430–7.
[PubMed Abstract](#) | [F1000 Recommendation](#)
37. Taketa T, Correa AM, Suzuki A, *et al.*: Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation. *Oncology.* 2012; 83(5): 300–4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
38. Suzuki A, Xiao L, Taketa T, *et al.*: Results of the baseline positron emission tomography can customize therapy of localized esophageal adenocarcinoma patients who achieve a clinical complete response after chemoradiation. *Ann Oncol.* 2013; 24(11): 2854–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
39. Elimova E, Wang X, Etcheberry E, *et al.*: 18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. *Eur J Cancer.* 2015; 51(17): 2545–52.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
40. zum Büschenfelde CM, Herrmann K, Schuster T, *et al.*: ¹⁸F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. *J Nucl Med.* 2011; 52(8): 1189–96.
[PubMed Abstract](#) | [Publisher Full Text](#)
41. Lordick F, Ott K, Krause BJ, *et al.*: PET to assess early metabolic response and to guide treatment of adenocarcinoma of the esophagogastric junction: the MUNICON phase II trial. *Lancet Oncol.* 2007; 8(9): 797–805.
[PubMed Abstract](#) | [Publisher Full Text](#)
42. **F** Dulak AM, Stojanov P, Peng S, *et al.*: Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. *Nat Genet.* 2013; 45(5): 478–86.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
43. **F** Nones K, Waddell N, Wayte N, *et al.*: Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. *Nat Commun.* 2014; 5: 5224.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
44. **F** Wang K, Johnson A, Ali SM, *et al.*: Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences. *Oncologist.* 2015; 20(10): 1132–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
45. **F** Secier M, Li X, de Silva N, *et al.*: Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. *Nat Genet.* 2016; 48(10): 1131–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
46. **F** Cancer Genome Atlas Research Network, Analysis Working Group: Asan University, BC Cancer Agency, *et al.*: Integrated genomic characterization of esophageal carcinoma. *Nature.* 2017; 541(7636): 169–75.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
47. **F** Cancer Genome Atlas Research Network: Comprehensive molecular characterization of gastric adenocarcinoma. *Nature.* 2014; 513(7517): 202–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
48. **F** Sharma P, Allison JP: The future of immune checkpoint therapy. *Science.* 2015; 348(6230): 56–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)

49. **F** Becht E, Giraldo NA, Dieu-Nosjean M, *et al.*: **Cancer immune contexture and immunotherapy.** *Curr Opin Immunol.* 2016; **39**: 7–13.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
50. Fareed KR, Kaye P, Soomro IN, *et al.*: **Biomarkers of response to therapy in oesophago-gastric cancer.** *Gut.* 2009; **58**(1): 127–43.
[PubMed Abstract](#) | [Publisher Full Text](#)
51. Liao Z, Liu H, Swisher SG, *et al.*: **Polymorphism at the 3'-UTR of the thymidylate synthase gene: a potential predictor for outcomes in Caucasian patients with esophageal adenocarcinoma treated with preoperative chemoradiation.** *Int J Radiat Oncol Biol Phys.* 2006; **64**(3): 700–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
52. Joshi MB, Shiota Y, Danenberg KD, *et al.*: **High gene expression of *TS1*, *GSTP1*, and *ERCC1* are risk factors for survival in patients treated with trimodality therapy for esophageal cancer.** *Clin Cancer Res.* 2005; **11**(6): 2215–21.
[PubMed Abstract](#) | [Publisher Full Text](#)
53. Skinner HD, Lee JH, Bhutani MS, *et al.*: **A validated miRNA profile predicts response to therapy in esophageal adenocarcinoma.** *Cancer.* 2014; **120**(23): 3635–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
54. **F** Hale MD, Nankivell M, Hutchins GG, *et al.*: **Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma: results from the UK MRC OE02 trial.** *Oncotarget.* 2016; **7**(47): 77565–75.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
55. **F** Reeh M, Effenberger KE, Koenig AM, *et al.*: **Circulating Tumor Cells as a Biomarker for Preoperative Prognostic Staging in Patients With Esophageal Cancer.** *Ann Surg.* 2015; **261**(6): 1124–30.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
56. Alix-Panabières C, Pantel K: **Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.** *Cancer Discov.* 2016; **6**(5): 479–91.
[PubMed Abstract](#) | [Publisher Full Text](#)
57. **F** Chaudhuri AA, Binkley MS, Osmundson EC, *et al.*: **Predicting Radiotherapy Responses and Treatment Outcomes Through Analysis of Circulating Tumor DNA.** *Semin Radiat Oncol.* 2015; **25**(4): 305–12.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
58. **F** Bidard FC, Peeters DJ, Fehm T, *et al.*: **Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.** *Lancet Oncol.* 2014; **15**(4): 406–14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
59. **F** Scher HI, Heller G, Molina A, *et al.*: **Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer.** *J Clin Oncol.* 2015; **33**(12): 1348–55.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
60. **F** Siravegna G, Mussolin B, Buscarino M, *et al.*: **Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.** *Nat Med.* 2015; **21**(7): 795–801.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
61. **F** Mohan S, Heitzer E, Ulz P, *et al.*: **Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing.** *PLoS Genet.* 2014; **10**(3): e1004271.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Efriede Bollschweiler**

General, Visceral and Cancer Surgery, University of Cologne, Köln, Germany

Competing Interests: No competing interests were disclosed.

2. **Rupert Langer**

Institute of Pathology, Bern, Switzerland

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research